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The physiological process of aging is undeniable complex. Changes in metabolism (i.e., 
increased fat and decreased water content, decreased liver function secondary to loss of 
hepatocytes leading to decreased metabolism, etc.) lead to an alteration in the pharmacokinetics 
and pharmacodynamics of medications in the body. A drug may accumulate in the serum of the 
body for a prolonged time secondary to diminished distribution. Disruption in the mechanism of 
drug metabolism may result in the elder individual experiencing adverse effects from the 
medication. The addition of morbidities into the mix enhances complexity whereby creating new 
challenges as the result is generally polypharmacy. Individuals with multiple chronic conditions 
are more likely to be on more medications. The more medications an individual is on increases 
their risk for drug to drug interactions and subsequent adverse effects. Providing care for an older 
individual (i.e., 60 or older), or an individual whose chronic conditions include dementia, 
requires additional care. This works will analyze a patient case involving multi-morbidities, 
dementia and polypharmacy. Through this patient situation, the need for interventions, such as 
de-prescribing will be clearly demonstrated.    
 Keywords: deprescribing, inappropriate prescribing, polypharmacy, dementia, elderly 
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De-prescribing, a Solution to the Issue of Polypharmacy: 
Case Report and Review  
Advancements in technology and ongoing discovery of new research findings in 
medicine have led to individuals having a longer life expectancy. According to the National 
Institute on Aging (2015), over half of the causation for the increase in life expectancy for 
females of developed countries between 1850 and 1900 can be attributed to these individuals 
living past 15 years of age. Prior to vaccinations, the culprits known for shortening the life 
expectancy included infectious and parasitic diseases. However, vaccinations are now widely 
available to counteract what used to be the "childhood killers." Individuals are living longer and 
with that comes new challenges. Development and progression of chronic disease, in addition to 
non-communicable diseases are among those challenges. Small strides have been made in the 
medical management of chronic conditions, however the percentage of the population affected is 
growing. Chronic disease was at one time, thought to be a death sentence. Learning how to 
effectively manage all the associated factors of chronic disease is challenging. The extent of this 
challenge is enhanced with the presence of co-morbid conditions. We continue to research these 
diseases and improve prevention and management methods.  
Chronic disease is further challenged by the normal physiological process of aging. The 
complications of aging with chronic disease requires polypharmacy, which brings with it 
additional risks. It is important to routinely review a patient’s medications to evaluate for 
necessity. According to the National Institute of Health (NIH, 2016), roughly fifteen percent of 
the population is 65 years or older. This age group contributes to thirty percent of outpatient 
prescription costs. Evidence shows that over half of community dwelling elderly individuals 
(ages 65 and older) in the USA and Australia have five or more daily medications. It 
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demonstrates a directly proportional relationship between aging and the number of routine 
medications.  
Potentially inappropriate medications (PIMs) can be described as the medications 
suggested to avoid prescribing to the elderly based on a clinical tool such as the AGS Beers 
Criteria, STOPP/START, or Medication Appropriateness Index (Cooper et al., 2015). Various 
studies have demonstrated the association between PIMs and adverse drug outcomes, 
hospitalizations, diminished quality or life as well as mortality. Utilizing interventions to prevent 
PIM and associated outcomes is longstanding. However, de-prescribing is a relatively new 
concept, which can be explained as cutting down or discontinuing medications with the intended 
outcomes of appropriate prescribing and elimination of the increased potential for adverse effects 
(Page, Clifford, Potter, Schwartz, & Etherton-Beer, 2016). The challenges of PMIs that 
necessitate an intervention such as de-prescribing, are clearly demonstrated in an unexpected 
case study involving an elderly patient with polypharmacy. The issue of polypharmacy is one 
that affects all age groups, in a variety of environments. The elderly population is vulnerable and 
as such, are at a higher risk for the detrimental effects of polypharmacy.  
Case Report 
A 59-year-old Caucasian, overweight woman with multiple active health problems 
presented to the clinic for follow-up on a recent hospitalization for UTI and fatigue. She had 
been discharged from the hospital four days earlier on nitrofurantoin, and had three days left. 
UTI symptoms were reportedly resolved. Endorsed ongoing fatigue for two months and noted a 
new complaint of intermittent dizziness, often positional. Otherwise, reported she felt well. Past 
medical history is significant for anemia, dementia, diabetes, COPD, hypertension, depression 
and neuropathy. At that time, she was taking 12 different scheduled medications including, daily 
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doses of losartan 50mg, furosemide 20mg and paroxetine 20mg, as well as twice daily doses of 
metoprolol 50mg and quetiapine 200mg. Also, 300mg of gabapentin was scheduled three times 
daily. As a resident at an assisted living apartment, she has staff to administer her medications. 
The patient presented hypotensive with bradycardia, blood pressure 88/40 and heart rate 
50. The remainder of her physical examination was fairly unremarkable. No apparent goiter, 
edema, abdominal tenderness or mass. Laboratory results included: thyroid stimulating hormone 
3.41 mI/UL, hemoglobin 12 g/dL, hematocrit 37%, platelets 400,000/mL, glucose 96 mg/dL, 
blood urea nitrogen 9 mg/dL, creatinine 0.8 mg/dL, sodium 140 mmol/L, potassium 3.9 mmol/L, 
aspartate aminotransferase 25 IU/L, alanine aminotransferase 11 IU/L, and albumin 4.1 gm/dL. 
ECG interpretation revealed sinus bradycardia, HR 48 bpm. Assessment dictated the following 
differential diagnoses: hypotension, hypothyroidism and anemia. Treatment for her hypotension 
included the following interventions: push fluids, decrease metoprolol to 25mg two times per 
day, discontinue furosemide, reduce dose of quetiapine to 150mg two times per day and return 
for follow up appointment in one week.  
Discussion 
The case study discussed demonstrates the strong impact of polypharmacy in the aging 
population. It denotes the importance of having the best interventions available. This leads to 
many questions: how does de-prescribing polypharmacy compared with other available 








           The intention of this work is to further explore the practice of de-prescribing, specifically 
in the older adult population. In the midst of this search, the author aimed to learn how de-
prescribing could be a solution to polypharmacy in aging individuals struggling with chronic 
multiple morbidities or comorbid conditions. A thorough review of the literature was 
accomplished by means of CINAHL, Cochrane, PubMed, and ScienceDirect electronic 
databases. McKeever, Nguyen, Peterson, Gomez-Perez, and Braunschweig (2016) recommended 
that a search of Mesh terms be conducted and, afterwards the Mesh terms should be listed with 
not "Medline [sb]". Separating the searches of Medline and not-Medline allow for the 
approximately 10% lost the by Medline search to be discovered through the second, not-Medline 
search. This method allows the researcher to conduct a gold-standard search that is both, 
proficient and clearly exhaustive to the reader. 
Through the use the PubMed database, the achievement of an exhaustive search is quite 
evident. The initial results were in the thousands. Limits were strategically placed to reduce the 
number of results. English was selected as a limit, with the focus on the human species and the 
full free text filter on to allow analysis of the documents entirety if selected. The 5-year limit was 
placed to ensure current research findings in the database. The Mesh terms, "Deprescriptions" or 
"Inappropriate Prescribing/prevention and control" or "Drug-Related Side Effects and Adverse 
Reactions/prevention and control" and "Humans" were searched in the sequence displayed. The 
related articles function was applied to limit the search. As previously noted, the not-Medline 
search was conducted with the same 4 phrase sequence, however with not "Medline [sb]" after 
"Humans". The not-Medline search yielded 31 findings, of which 10 met the criteria. 
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Mateo and Foreman (2014) stressed that a researcher should use multiple databases 
throughout their research to ensure that important findings are not missed. Keywords 
"deprescription" and "elderly" were terms searched utilizing the ScienceDirect database. Limits 
were not necessary. The search yielded 14 results, with only 2 being applicable to this works. 
The CINAHL database was employed through the Boolean/Phrase search mode. The following 
terms were utilized: “deprescribing” or “inappropriate prescribing” and “elderly”. In an effort to 
decrease the number of findings the limits placed include: publication date between 2014 and 
2017 for current results, and the English language. Results produced in the search were over 100. 
Terms searched for on the Cochrane database include: “deprescribe” or “polypharmacy” or 
“inappropriate prescribing or medical overuse”. A total of 21 results were yielded in this search. 
The results of the PubMed, CINAHL, ScienceDirect and Cochrane databases were sifted 
through to determine the relevant findings. This proved to be a challenging task as the majority 
of the research findings in the listed databases were considered irrelevant to the author. In light 
of this, additional studies were discovered through utilizing the “snowball” approach. Analysis 
was completed on 11 of the articles discovered during these searches.    
Grading the Evidence 
Classification of evidence via a level grading system allows for the promotion of 
confidence in the researcher’s findings. The evidence found throughout this research was graded 
based on the AACN’s New Evidence-Leveling System. This system ranges from levels A-E and 
M with the highest level starting at level A and the lowest level M.  
Level A is classified as meta-analysis of controlled studies or meta-synthesis of 
qualitative studies (Armola et. al, 2009). Randomized and non-randomized controlled studies are 
level B evidence. Descriptive, correlational and quantitative studies as well as randomized 
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controlled and systematic or integrative reviews with findings that are inconsistent would be 
classified as level C evidence. Level D evidence includes clinical guidelines by professional 
organizations that have been peer-reviewed. Case studies or expert opinions based on theory are 
classified as level E evidence. The recommendations provided by a manufacturer is graded as 
level M (Armola et. al, 2009).  
The mission of the American Association of Critical Care Nurses (AACN) focuses on the 
development of interventions that will lead to a better understanding of the resources in question 
to allow members of the nursing profession to determine the best possible evidence for clinical 
practice (Armola et. al, 2009). As a member of the nursing professional and a goal to yield strong 
evidence for clinical practice, the AACN’s hierarchy of evidence is indubitably appropriate. The 
levels of evidence for the 11 studies analyzed are as follows: 2 randomized control studies 
(RCTs) fit the criteria for level B, and the remaining 9 fit the criteria for level C. All of the 7 
level C studies are systematic review and/or meta-analysis that revealed inconsistent, 
heterogeneous findings.    
Synthesis of Findings 
Cooper et al. (2015) demonstrated how validated screening tools (i.e., Medication 
Appropriateness Index(MAI), Beers’ Criteria, Mcleod criteria, STOPP/START criteria, 
Assessment of Underutilization of Medication and ACOVE) effectively reduce potentially 
inappropriate prescribing (PIMs) in individuals ages 65 and older. It was noted that some of the 
studies in the review did not consider the reverse effect of under-prescribing, which is another 
major issue (especially in the older population). Utilization of MAI revealed a statistically 
significant decrease in PIM. In addition, the other tools previously mentioned divulged a 
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reduction as well though not significant. Unfortunately, the results of this review were 
inconsistent which decreases its validity.  
Another systemic review demonstrated similar findings regarding reductions in MAI in a 
study population ages 65 and older, however there was additional focus on the presence of 
dementia (Walsh, O’Riordan, Kearney, Timmons, & Byrne, 2016). The importance of reducing 
PIM in individuals with dementia is amplified. This disease enhances the likelihood of the 
individual experiencing an adverse effect as a result of polypharmacy, specifically 
anticholinergics, antipsychotics, and benzodiazepines (Walsh, O’Riordan, Kearney, Timmons, & 
Byrne, 2016). Our case patient came into the clinic on a high dose of quetiapine which is often 
used in addition to an anti-depressant. This is likely why the patient in the case study has both 
paroxetine and quetiapine on her active medication list. It is known that many of the mental 
health medications carry a black box warning. Quetiapine is an anti-psychotic that holds a 
blackbox warning. Its use in patients who are elderly with psychosis secondary to dementia 
heightens their mortality risk. Antipsychotics increase the risk that the patient with dementia will 
experience a cerebrovascular accident (American Geriatrics Society, 2015).  
According to the Beers criteria (2015), paroxetine and quetiapine should be avoided in 
ages 65 and older. The criteria states that quetiapine should not be administered to individuals 
with dementia. Our case patient is younger than 65, however with her diagnosis of dementia and 
multi-morbidities quetiapine is inappropriate. Her current medication list includes three CNS-
active medications. This medication regimen places her at risk for adverse CNS effects, and 
likely are at least partially to blame for her complaints of dizziness and persistent fatigue. The 
furosemide and metoprolol are likely contributors to this as well.     
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     Interventions to improve patient adherence to medication regimens revealed 
statistically significant increases in secondary outcomes including knowledge, physical 
functioning, overall quality of life and general mood, cardiac and respiratory symptoms (Conn, 
Ruppar, Enriquez, & Cooper, 2016). This demonstrates the importance of patient-centered 
interventions to achieve patient-centered outcomes. Fried et al. (2014) found evidence indicating 
de-prescribing can reverse symptoms. The evidence also showed that in addition to improvement 
of physical functioning, de-prescribing enhances cognitive function. Interestingly, Scott, 
Anderson, Freeman, and Stowasser (2014) demonstrated common themes related to barriers as 
well as facilitators influencing the ruction of PIM. The themes discovered include awareness, 
inertia (i.e. fear of the unknown), and self-efficacy (i.e., knowledge). Perhaps the educational 
interventions for improving patient adherence to medication regimens mentioned earlier in this 
paragraph would be effective interventions to the themes. Patients are much more likely to agree 
with a plan for de-prescribing if they are cued in as to why. Reeve et al. (2013) identified barriers 
and facilitators influencing patient agreement to de-prescribing. Understanding the 
“appropriateness” of de-prescribing is one of the themes, which again indicates the need for 
education.    
According to Page, Clifford, Potter, Schwartz, and Etherton-Beer (2016), de-prescribing 
exhibited a statistically significant decrease in mortality in two non-randomized control trials. A 
systematic review including 19 studies implemented by Johansson et al. (2016) demonstrated a 
downward trend in mortality associated with ongoing follow-ups post-hospitalization. Physician-
led medication review verified statistically significant outcomes through reduction of PIM use in 
the elderly (Tjia, Velten, Parsons, Valluri, & Briesache, 2013). Johansson et al. (2016) found 
minimal evidence supporting reductions in hospital admissions secondary to reductions in PIM 
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through a multi-disciplinary approach to medication review. One study showed a non-
statistically significant decrease in hospital admission. Whereas, Dreischulte et al. (2016) 
demonstrated statistically significant reductions in hospital admissions for gastrointestinal bleeds 
and heart failure. The results were non-statistically significant for acute kidney injury. Perhaps 
the difference is related to the kidneys role in metabolism. Clyne (2015) verified the efficiency of 
the pharmacist-led medication review in reducing PIM. This involved the utilization of OPTI-
SCRIPT, which led to statistically significant reductions in proton pump inhibitors. Results for 
all studies discussed are in Table 1. 
De-prescribing involves a great deal more than the term implies. Multiple factors must be 
taken into consideration including, a collaborative agreement between the patient and their 
provider. Evidence supports the recommendation of de-prescribing, however this is often not 
performed by providers secondary to challenges including time constraints and lack of patient 
centered guidelines. More than a quarter of medications de-prescribed are re-initiated in less than 
a year’s time. Re-initiation of previously de-prescribed medications has resulted in adverse 
patient outcomes (Scott, Anderson, Freeman, & Stowasser, 2014). It is clear that de-prescribing 
has shown beneficial outcomes. However, in order for this to be a successful intervention there 
must be a patient-provider relationship built on trust. 
When a provider is faced with the decision of whether or not to discontinue a medication, 
the most important aspect that must be considered is the risks verses the benefits. This should 
include the preferences of the patient and their family in addition to the availability of non-
pharmacological treatment alternatives. The second step involves collaboration with the patient 
and their family regarding the discontinuation process. Planning the strategy is the final step, 
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which should include a discussion with the patient regarding if and when the medication should 
be re-initiated (Ferral, 2017). 
The issue of polypharmacy is one that affects all age groups, in a variety of 
environments. The elderly population is vulnerable and as such, are at a higher risk for the 
detrimental effects of polypharmacy. Of the promising interventions known to combat this 
problem, deprescribing is a more recent development with the potential to minimize the effects 
of multiple medications use. Polypharmacy in older adults has been shown to yield many 
negative results. This age group often carries with it a collection of multiple health problems, 
leading to multiple medications and ultimately, polypharmacy. As a complication, the utilization 
of multiple medications in the same elderly individual may end up in harm through adverse 
effects, altered cognition, falls, as well as hospitalization or death. 
De-prescribing is not merely a method of reducing medications; it should be utilized in an 
effort to eliminate inappropriate medications. Polypharmacy in older adults has been shown to 
yield many negative results. This age group often carries with it a collection of multiple health 
problems, leading to multiple medications and ultimately, polypharmacy. As a complication, the 
utilization of multiple medications in the same elderly individual may end up in harm through 
adverse effects, altered cognition, falls, as well as hospitalization or death. Farrell et al. (2016) 
developed guidelines for the de-prescribing process for patients 18 and older. The intention was 
to construct a set of guidelines specific to the elderly population, however a decision was made 
to broaden the age span based on the literature revealing insufficient evidence for this age group.  
There is a plethora of research indicating the severity of the issue regarding 
polypharmacy in the elderly population, however there is a lack of consistent evidence 
supporting de-prescribing and other interventions to reduce polypharmacy. Concrete evidence is 
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necessary for change. As outlined in this works, the age group with the greatest propensity of 
harm as a result of polypharmacy is the elderly. For this reason, as well as the obvious 
differences that are a consequence of aging (physiological vs. pathological), there should be a 
separate set of guidelines for individuals ages 65 and older. This necessitates the attention of the 
members in the health care community. It has been made abundantly clear that the elderly 
population, ages 65 and older, is vulnerable. Additional research needs to be conducted to 
determine how to further define the criteria for specific guidelines for this population. 
Learning Points 
1) When making a decision about whether or not to discontinue a medication, the emphasis 
should be placed on the benefits versus risks.  
2) The art of de-prescribing should be a patient-centered approach. This means considering 
the preferences of the patient and their family and collaborating throughout the entire 
process.    
3) It is clear that de-prescribing has shown beneficial outcomes. However, in order for this 
to be a successful intervention there must be a patient- provider relationship built on trust. 
4) Deprescribing should place a greater emphasis on the technique of prescribing rather than 
simply focusing on a decrease in medications prescribed. 
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11 studies on pharmaceutical 
care based intervention using a 
validated assessment tool  
 
4 studies on patient education 
and tools to schedule 
medications to improve 
compliance 
 
5 studies on education to health 
care providers and team 
members 
 
A single unifacitated study on 
computerized decision support 
 
7 validated screening tools were 
utilized in the 12 studies (i.e, 
Medication Appropriateness 
Index, Beers' Criteria, Mcleod 
criteria, STOPP/START criteria, 
Assessment of Underutilization 
of Medication and ACOVE) 
 
Some studies focused on the 
reduction of polypharmacy 
without considering the 
Evaluation of quality of evidence 
utilizing a GRADE approach 
 
Randomization utilized in all 
studies 
 
No language restrictions 
 
Studies with small sample size 
and low quality based on GRADE 
approach, resultant increased risk 
of bias 
 
Lack of allocation concealment 
and protection against 
contamination 
 
Studies lacking a validated 
assessment of under-prescribing 
 
Effect estimate inaccuracy 
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occurrence of the opposite effect 
(i.e., under-prescribing) 
 
Significant reduction in 
inappropriate prescribing using 
MAI  
 
Reduction using the other tools 
compared to no using a tool 
 
Interventions not effective 
against ADEs and 
























Data collection via coding frame 
 
Statistically significant results 
were revealed in knowledge of 
medication, function, specified 
symptoms (i.e., depression, pain, 
energy, cardiac and respiratory 
and overall quality of life. 
 
The most significant increase 
was found in knowledge  
 
Patient centered outcomes were 
moderately increased post-
interventions   
 
 
Most studies utilized random 
assignment 
 
Use of allocation concealment  
 
Presence of heterogeneous results 
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Studies: 15 RCT, 4 non-RCT, 6 




review: 6 of 12 demonstrated 
statistical analysis with 4 of the 6 
noting results that were 
statistically significant. The 
other 6 indicated variable results. 
 
Multi-disciplinary approach: 10 
of 13 revealed statistical analysis 




medication reductions occurred 
in 4 of 4 studies on academic 
detailing, 5 of 5 studies of 
medication reviews by 
physicians and in audit/feedback  
 
Direct relationship noted 
between presence of cohort 
group and strength of study  
Multiple studies with moderate to 
high risk of bias secondary to 
failing to adjust for potential 
confounding variables as well as 
non-blinded assessment of 
outcomes 
 
Heterogeneity of results, unable 























comprehensive review utilizing 
12 electronic databases 
  
reductions in MAI were 
statistically significant in 3 
RTCs utilizing tools 
 



































Evidence shows that de-
prescribing is practical, may not 
influence mortality 
 
Evidence is available to guide a 
provider when the situation fits a 
classic presentation meaning 
there is a lack of applicability in 
the guidelines 
  
Statistically significant reduction 
in mortality with de-prescribing 
revealed in non-RTCs, not 
significant in RTCs 
 
   
Potential for language bias, limit 
placed for English 
 
Broad inclusion criteria 
 
Potential for bias based on 
methodology 
 























N= 58 Data elements included: design, 
population, measure of 
polypharmacy and main 
findings. 
 
All observational studies, most 
cross sectional or longitudinal 
cohort studies, few were case 
control 
 
Adjustments were made for 
confounding variables (i.e., 
chronic conditions) 
 
Large and population based 
cohort studies 
  
Studies analyzed are 
observational studies, 
confounding is a greater issue  
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23 studies analyzed falls as the 
health outcome of 
polypharmacy.  
- 14 of 23 studies were rated 
good.  
- 12 of 14 found positive 
association between 
polypharmacy and the outcome. 
Greater polypharmacy showed 
association to outcomes, whereas 
1-3 medications did not show 
association.    
 
14 studies analyzed ADEs as the 
health outcome of 
polypharmacy.  
- 8 of 14 studies were rated 
good. - 5 of 8 found association.  
- 1 of the 5 showed association 
only at use of 14 medications.  
- 6 of 14 studies were rated fair 
or poor and 4 of the 6 found an 
association 
 
10 studies analyzed 
hospitalization or mortality as 
the health outcome of 
polypharmacy.  
- 4 of the 10 were rated good and 
found associations with the 
outcome.  
- 6 of 10 were rated fair or poor 
and 3 of 6 found association 
 




15 studies analyzed multiple 
health outcomes of 
polypharmacy including 
symptoms, function and 
cognition.  
- 11 of 15 studies were rated 
good and all 11 found 
association with one or more 
outcomes.  
 
A single study analyzed the 
potential development of 
Parkinson’s disease as the health 



























Outcome measured was patient 
exposure to 1 of 9 anti-




revealed statistically significant 
results found include decreased 
admission to the hospital for 
gastrointestinal bleed and heart 
failure 
 
Results were not significant 
regarding hospital admission for 




Evaluation completed in primary 
care 
 
Continued positive outcomes 










































Study focus: ages 65 and older 
with polypharmacy (4 or more 
medications) 
 
Interventions included electronic 
based and non-electronic based 
(i.e., Beers’ criteria)  
- pharmacist, physician or 
multiple discipline-led 




Hospitalization- 11 studies, 2 
showed significant results, others 
were inconsistent 
Mortality- 19 studies, revealed a 
downward trend with longer 
follow up period inconsistent 
results 
Approach to assess quality 
involved utilization of the Grade 
Pro Tool 
 
























Statistically significant results 
found in the reduction of 
inappropriate prescribing of 
proton pump inhibitors utilizing 
the OPTI-SCRIPT intervention. 
 
OPTI-SCRIPT incorporates the 
review of medications, pharmacy 
visit to discuss potentially 
inappropriate medications and 
the pharmaceutical based 
treatments guides on the web 
Relevance to clinical practice 
 
Retention of study participants 
 
Potential selection bias reduced 
via data collection by independent 
third party prior to minimization. 
 
Blindness to allocation 
 
Setting in primary care with 
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N= 21 Analysis of study design and 
aims, location and setting, 
participants and enrollment 
process, viewpoints of 
provider/prescriber, PIMs    
 
Methods included descriptive 
survey, SSIs, interviews, group 
discussions, focus groups  
 
Utilization of focus groups and 
partly structured interviews  
 
Development of descriptive and 
analytical themes utilizing 
subthemes discovered 
 
Collection through thematic 
synthesis yielded 42 subthemes, 
12 descriptive themes and 4 
analytical themes 
 
Intrinsic themes:  
1) Awareness (i.e., poor insight, 
discrepant beliefs and practice), 
2) Inertia (i.e., fear of 
unknown/negative outcome, 
medication effect greater benefit 
than risk, prescribing is desired 
by patient, challenge of cessation 
and low priority) 
Assessment of quality utilizing 
COREQ 
-Ave score 17 (range 8—22) 
-Better assessment of credibility, 
dependability and transferability 
of findings  
 
Consistency with raw data 
 
Interpretations were peer 
reviewed, (aside for 1)  
 
Obedience with reporting 
requirements of ENTREQ  
 
COREQ: researcher bias could 
not be excluded 
 
Ethics approval indeterminable in 
5 studies 
 
Terminology inconsistency and 
poor indexing of search terms 
interference with study findings 
 
Only 4 studies on polypharmacy, 
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3) Self-efficacy (i.e., skills, 
knowledge) 
 
Extrinsic theme:  
1) Feasibility (i.e., patient 
resistance to change, limited 
alternatives, time/effort needed 
to de-prescribe) 
 












leading to a 
patient decision 









Content analysis with coding 
 
Data extracted via two reviewers 
through standardized data 
extraction 
 
Method included principles of 
systematic review of quantitative 
and qualitative research 
 
Categories determined at time of 
review 
Data was extracted and 
categorized then divided into 
themes and subthemes  
 




Variability in completeness of 
reporting 
 
Utilization of quantitative and 
qualitative studies 
  
Uncertainty of true 
inappropriateness of a medication 
in question for de-prescription. 
 
Studies included all age groups, 
the variation between adolescence 
and elderly must be considered. 
Themes were found to be similar.  
 
Only able to use published data, 
which equates to an inability to 
support the idea that the only 
factors relevant to prescribing are 
the factors discussed in this 









1) Viewpoint regarding 
“appropriateness” of de-
prescription 
2) Availability of a process for 
de-prescribing  
3) Influences 
4) Fright or dislike 
 
Most common was 
“appropriateness of de-
prescribing- 18 studies found it 
to be a facilitator, 15 found it to 
be a barrier 
 
20 studies on single medication 
class or therapeutic group, a 
single study on any chronic med 
 
De-prescribing should be patient 
centered 
 
Patients need to be educated on 
why the medication is 
inappropriate (i.e., side effects 
can occur at any time) 
Studies focused only on 
commonly utilized medications 
 
Quality assessment was not 
formal. Results were poor as most 
studies had mixed methodology 
 
Potential for personal and 
publication bias as this is these 
are qualitative studies 
 
 
     
 
 
     





Randomized Control Trial (RCT) 
Consolidated Criteria for Reporting Qualitative Research (COREQ) 
Potentially inappropriate medications (PIMs)  
Grades of Recommendation Assessment, Development and Evaluation (GRADE) 
 Optimizing Prescribing for Older People in Primary Care, a cluster-randomized controlled trial (OPTI-SCRIPT study) 
 
